Autopsy report · NCT04044170

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

“Study termination by the Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Hanmi Pharmaceutical Company Limited

Sponsor type

Industry

Conditions

NSCLC

Interventions

Poziotinib

Participants

5

Sites

26

Countries

China, South Korea

Trials that died the same way

• Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
  “Sponsor terminated study” (92% match in meaning)
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
  “Sponsor decision to terminate study.” (92% match in meaning)
• Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
  “Study Terminated by Sponsor” (91% match in meaning)
• Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients
  “Study terminated by the Sponsor” (90% match in meaning)
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.